Paradigm Biopharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Paradigm Biopharmaceuticals CEO'su Paul Rennie, Jan2014 tarihinde atandı, in görev süresi 10.83 yıldır. in toplam yıllık tazminatı A$ 1.10M olup, şirket hissesi ve opsiyonları dahil olmak üzere 86.5% maaş ve 13.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.72% ine doğrudan sahiptir ve bu hisseler A$ 2.58M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 4.1 yıldır.

Anahtar bilgiler

Paul Rennie

İcra Kurulu Başkanı

AU$1.1m

Toplam tazminat

CEO maaş yüzdesi	86.5%
CEO görev süresi	10.8yrs
CEO sahipliği	2.7%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	4.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Paul Rennie'un ücretlendirmesi Paradigm Biopharmaceuticals'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$1m	AU$948k	-AU$59m
Mar 31 2024	n/a	n/a	-AU$64m
Dec 31 2023	n/a	n/a	-AU$69m
Sep 30 2023	n/a	n/a	-AU$60m
Jun 30 2023	AU$2m	AU$602k	-AU$52m
Mar 31 2023	n/a	n/a	-AU$48m
Dec 31 2022	n/a	n/a	-AU$44m
Sep 30 2022	n/a	n/a	-AU$42m
Jun 30 2022	AU$1m	AU$219k	-AU$39m
Mar 31 2022	n/a	n/a	-AU$40m
Dec 31 2021	n/a	n/a	-AU$41m
Sep 30 2021	n/a	n/a	-AU$37m
Jun 30 2021	AU$1m	AU$510k	-AU$34m
Mar 31 2021	n/a	n/a	-AU$31m
Dec 31 2020	n/a	n/a	-AU$28m
Sep 30 2020	n/a	n/a	-AU$20m
Jun 30 2020	AU$632k	AU$462k	-AU$12m
Mar 31 2020	n/a	n/a	-AU$14m
Dec 31 2019	n/a	n/a	-AU$16m
Sep 30 2019	n/a	n/a	-AU$16m
Jun 30 2019	AU$1m	AU$420k	-AU$16m
Mar 31 2019	n/a	n/a	-AU$11m
Dec 31 2018	n/a	n/a	-AU$7m
Sep 30 2018	n/a	n/a	-AU$7m
Jun 30 2018	AU$573k	AU$380k	-AU$6m

Tazminat ve Piyasa: Paul 'nin toplam tazminatı ($USD 714.61K ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 298.55K ).

Tazminat ve Kazançlar: Paul 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Paul Rennie (65 yo)

10.8yrs

Görev süresi

AU$1,096,287

Tazminat

Mr. Paul John Rennie, BSc, MBM, Grad Dip Commercial Law, MSTC, served as Independent Non-Executive Chairman at NeuroScientific Biopharmaceuticals Limited since June 21, 2021 until November 23, 2022, was it...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Paul Rennie	Founder	10.8yrs	AU$1.10m	2.72% A$ 2.6m
Donna Skerrett	Chief Medical Officer and Executive Director	2.3yrs	AU$1.23m	0.31% A$ 295.5k
Abby Macnish Niven	Company Secretary & CFO	2.3yrs	Veri yok	Veri yok
Ravi Krishnan	Chief Scientific Officer	9.2yrs	Veri yok	Veri yok
Simon White	Director of Investor Relations	no data	Veri yok	Veri yok
Michael Imperiale	Global Head of Drug Safety & MPS	4.4yrs	Veri yok	Veri yok
Beverley Huttmann	Commercial Head	4.1yrs	Veri yok	Veri yok
Michelle Coffey	Global Head of Regulatory Affairs	no data	Veri yok	Veri yok
Mukesh Ahuja	Global Clinical Head of OA	no data	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

Deneyimli Yönetim: PAR 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Paul Rennie	Founder	10.5yrs	AU$1.10m	2.72% A$ 2.6m
Donna Skerrett	Chief Medical Officer and Executive Director	4.3yrs	AU$1.23m	0.31% A$ 295.5k
Amos Meltzer	Independent & Non-Executive Director	3.9yrs	AU$88.80k	Veri yok
Matthew Fry	Independent Non-Executive Director	less than a year	AU$24.24k	0.41% A$ 383.4k

4.1yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PAR 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.1 yıldır).

Paradigm Biopharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

Insufficient new directors

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Recent updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New major risk - Financial position

New minor risk - Profitability

Insufficient new directors

New major risk - Financial position

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.21 loss per share (vs AU$0.17 loss in FY 2022)

Founder recently bought AU$76k worth of stock

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Forecast to breakeven in 2024

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

New 90-day low: AU$2.30

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

New 90-day low: AU$2.38

New 90-day low: AU$2.42

Paradigm Biopharmaceuticals Ltd Receives the Written Response from the Type-C meeting with the US Food and Drug Administration (FDA) regarding Zilosul® for the Treatment of Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces Resignation of Chris Fullerton as Non- Executive Director

Paradigm Biopharmaceuticals Limited Announces First Patient Dosed in Phase 2 Clinical Trial Evaluating PPS in Mucopulysaccharidoses Type-1

Paradigm Biopharmaceuticals Limited Adds Senior Executives to its Team

Paradigm Biopharmaceuticals Ltd Clear Path Towards Zilosul's Oa Phase 3 Clinical Trial and Product Registration in Europe

Paradigm Biopharmaceuticals Ltd Reports Additional Data on Patients Who Received Zilosul® Under the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS)

New 90-day low: AU$2.32

New 90-day low - AU$2.54

Paradigm Biopharmaceuticals Limited(ASX:PAR) dropped from S&P/ASX Emerging Companies Index

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi